

Supplementary Materials

Title:

Overlapping Extremes: An Analysis of Avelumab Maintenance and Pembrolizumab in Advanced Urothelial Carcinoma

Authors:

Martina Catalano, Irene de Gennaro, Ismaela Vascotto, Adriana Guarino, Silvia Mancini, Laura Doni, Alexandra Paulet, Virginia Rossi, Roberta Giorgione, Gabriella Nesi, Lorenzo Antonuzzo, Giandomenico Roviello**

Affiliations:

- 1. Department of Health Science, University of Florence, Florence, Italy*
- 2. Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy*
- 3. Clinical Oncology Unit, Careggi University Hospital, Florence, Italy*
- 4. Department of Health Sciences, Section of Anatomic Pathology, University of Florence, Florence, Italy*

Corresponding Author:

Giandomenico Roviello, MD, PhD

*Department of Health Sciences, Section of Clinical Pharmacology and Oncology
University of Florence*

Viale Pieraccini 6, 50139, Florence, Italy

E-mail: giandomenico.roviello@unifi.it

Figure 1S. Distribution of Tumour Response Rates in Patients Treated with Avelumab, Pembrolizumab, and in the Overall Cohort. Abbreviations: , CR = Complete Response, PR = Partial Response, SD = Stable Disease, , RR = Response Rate; DCR = Disease Control Rate ; PD = Progressive Disease.

